{
    "clinical_study": {
        "@rank": "72276", 
        "acronym": "Hydrus V", 
        "arm_group": [
            {
                "arm_group_label": "Hydrus Microstent", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to the Hydrus Microstent ."
            }, 
            {
                "arm_group_label": "iStent Trabecular Micro Bypass", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients randomized to the iStent Trabecular Micro Bypass"
            }
        ], 
        "brief_summary": {
            "textblock": "This clinical trial compares two implantable devices intended to lower the pressure inside\n      the eye of glaucoma patients."
        }, 
        "brief_title": "Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Open Angle Glaucoma", 
            "Pseudoexfoliative Glaucoma", 
            "Pigmentary Glaucoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter, single-masked, randomized clinical trial comparing the\n      Hydrus Microstent to two iStent implants for the reduction of intraocular pressure in phakic\n      patients with a positive diagnosis of primary open angle glaucoma, pseudoexfoliative\n      glaucoma, or pigmentary dispersion glaucoma.  Post-operative follow-up visits will be\n      conducted at regular intervals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A diagnosis of primary open angle glaucoma (POAG), Pseudoexfoliative (PXG) glaucoma,\n             or Pigmentary glaucoma (PG)\n\n          -  A phakic lens with BCVA of 20/30 or better\n\n        Exclusion Criteria:\n\n          -  Forms of primary or secondary glaucoma not listed above\n\n          -  Prior glaucoma surgery in the study eye"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023242", 
            "org_study_id": "CP-12-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hydrus Microstent", 
                "description": "Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.", 
                "intervention_name": "Hydrus Microstent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "iStent Trabecular Micro Bypass", 
                "description": "Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.", 
                "intervention_name": "iStent Trabecular Micro Bypass", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Primary open angle glaucoma", 
            "POAG", 
            "Pseudoexfoliative glaucoma", 
            "PXG", 
            "Pigmentary glaucoma", 
            "PG", 
            "Hydrus"
        ], 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Irvine", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92618"
                }, 
                "name": "Contact Brett Trauthen at Ivantis"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Randomized Comparison of the Hydrus to the iStent\u00ae for Lowering Intraocular Pressure in Primary Open Angle Glaucoma", 
        "other_outcome": {
            "description": "Safety outcomes include complications and adverse events.", 
            "measure": "Safety outcomes", 
            "safety_issue": "Yes", 
            "time_frame": "Months 12 and 24"
        }, 
        "overall_contact": {
            "email": "btrauthen@ivantisinc.com", 
            "last_name": "Brett Trauthen", 
            "phone": "949/333-1315"
        }, 
        "overall_contact_backup": {
            "email": "prhee@ivantisinc.com", 
            "last_name": "Paul Rhee, OD", 
            "phone": "949/333-1316"
        }, 
        "overall_official": {
            "affiliation": "Madrid, Spain", 
            "last_name": "Julian Garcia Feijoo, Prof. Med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Poland: Ethics Committee", 
                "Italy: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Mexico: Ministry of Health", 
                "Chile: Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary effectiveness endpoint for this study is IOP at 12 months following surgery.", 
            "measure": "Intraocular pressure at Month 12", 
            "safety_issue": "No", 
            "time_frame": "Twelve months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023242"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Mean medication use at 12 and 24 months post procedure", 
            "measure": "Medication use at 12 and 24 months", 
            "safety_issue": "No", 
            "time_frame": "Months 12 and 24"
        }, 
        "source": "Ivantis, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ivantis, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}